MiR-200c inhibits bladder cancer progression by targeting lactate dehydrogenase A

Daozhang Yuan; Shunsheng Zheng; Liyan Wang; Jing Li; Jianan Yang; Bin Wang; Xiong Chen; Xiaobo Zhang

doi:10.18632/oncotarget.18801

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MiR-200c inhibits bladder cancer progression by targeting lactate dehydrogenase A

Daozhang Yuan _, Shunsheng Zheng, Liyan Wang, Jing Li, Jianan Yang, Bin Wang, Xiong Chen and Xiaobo Zhang

PDF | HTML | How to cite

Oncotarget. 2017; 8:67663-67669. https://doi.org/10.18632/oncotarget.18801

Metrics: PDF 2596 views | HTML 2520 views | ?

Abstract

Daozhang Yuan1, Shunsheng Zheng1, Liyan Wang1, Jing Li1, Jianan Yang1, Bin Wang1, Xiong Chen2 and Xiaobo Zhang2

1Department of Urology, Cancer Center of Guangzhou Medical University, Guangzhou, People’s Republic of China

2Department of Geriatric Medicine, Xiangya Hospital, Central South University, Changsha, People’s Republic of China

Correspondence to:

Daozhang Yuan, email: [email protected]

Xiaobo Zhang, email: [email protected]

Keywords: microRNA, miR-200c, LDHA, bladder cancer, proliferation

Received: November 09, 2016 Accepted: June 02, 2017 Published: June 28, 2017

ABSTRACT

Lactate dehydrogenase A (LDHA) is overexpressed in various cancers. We investigated LDHA expression and function in bladder cancer. We demonstrate that LDHA is up-regulated in bladder cancer cells and promotes proliferation, invasion, and glycolysis. Additionally, we found that microRNA (miR)-200c directly targets LDHA in bladder cancer cells. Ectopic expression of miR-200c inhibited LDHA-induced glycolysis, cell proliferation, and invasion. Thus, targeting LDHA through miR-200c is a potential therapeutic strategy in bladder cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18801

Publication Alerts

Post-Publication Promotion

Research Papers:

MiR-200c inhibits bladder cancer progression by targeting lactate dehydrogenase A

Abstract